Peter Lachman

Peter Lachman is a seasoned professional in business development and investment banking, currently serving as Senior Director of Business Development at Caribou Biosciences since 2024. Prior experience includes roles at Sarepta Therapeutics focusing on business development and M&A, as well as investment banking at Leerink Partners. Lachman's investment expertise spans private equity and venture capital with SAIGroup and Corporate Fuel Partners, while having contributed as a Board Observer for multiple companies including EnergyWatch and Genisphere. Early career achievements include significant roles at Amex Ventures and Morgan Stanley, with notable transactions such as the $2.6 billion sale of Auxilium Pharmaceuticals and the $173 million IPO of Diplomat Pharmacy. Educational credentials include an MBA from NYU Stern, an MPhil from the University of Cambridge, and a BA from Fordham University.